156 related articles for article (PubMed ID: 37217164)
1. How do we image patients with multiple myeloma and precursor states?
Chakraborty R; Hillengass J; Lentzsch S
Br J Haematol; 2023 Nov; 203(4):536-545. PubMed ID: 37217164
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Whole-Body DWI and
Chen J; Li C; Tian Y; Xiao Q; Deng M; Hu H; Wen B; He Y
AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755
[No Abstract] [Full Text] [Related]
4. Hybrid simultaneous whole-body 2-[
Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of
Basha MAA; Hamed MAG; Refaat R; AlAzzazy MZ; Bessar MA; Mohamed EM; Ahmed AF; Tantawy HF; Altaher KM; Obaya AA; Afifi AHM
Jpn J Radiol; 2018 Jun; 36(6):382-393. PubMed ID: 29671193
[TBL] [Abstract][Full Text] [Related]
6. Imaging in myeloma with focus on advanced imaging techniques.
Barwick T; Bretsztajn L; Wallitt K; Amiras D; Rockall A; Messiou C
Br J Radiol; 2019 Mar; 92(1095):20180768. PubMed ID: 30604631
[TBL] [Abstract][Full Text] [Related]
7. Optimization of whole-body 2-[
Burns R; Mulé S; Blanc-Durand P; Tofighi M; Belhadj K; Zerbib P; Le Bras F; Baranes L; Haioun C; Itti E; Luciani A
Eur Radiol; 2022 May; 32(5):3085-3096. PubMed ID: 34842956
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
9. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
[TBL] [Abstract][Full Text] [Related]
12. Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas.
Maccioni F; Alfieri G; Assanto GM; Mattone M; Gentiloni Silveri G; Viola F; De Maio A; Frantellizzi V; Di Rocco A; De Vincentis G; Pulsoni A; Martelli M; Catalano C
Radiol Med; 2023 May; 128(5):556-564. PubMed ID: 37145214
[TBL] [Abstract][Full Text] [Related]
13. The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with
Paternain A; García-Velloso MJ; Rosales JJ; Ezponda A; Soriano I; Elorz M; Rodríguez-Otero P; Aquerreta JD
Eur J Radiol; 2020 Dec; 133():109403. PubMed ID: 33202373
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Updates in the Role of Imaging for Multiple Myeloma Management Based on Recent International Guidelines.
Lee K; Kim KW; Ko Y; Park HY; Chae EJ; Lee JH; Ryu JS; Chung HW
Korean J Radiol; 2021 Sep; 22(9):1497-1513. PubMed ID: 34448381
[TBL] [Abstract][Full Text] [Related]
15. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
16. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma.
Hur J; Yoon CS; Ryu YH; Yun MJ; Suh JS
Acta Radiol; 2008 May; 49(4):427-35. PubMed ID: 18415787
[TBL] [Abstract][Full Text] [Related]
18. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Lecouvet FE; Vekemans MC; Van Den Berghe T; Verstraete K; Kirchgesner T; Acid S; Malghem J; Wuts J; Hillengass J; Vandecaveye V; Jamar F; Gheysens O; Vande Berg BC
Skeletal Radiol; 2022 Jan; 51(1):59-80. PubMed ID: 34363522
[TBL] [Abstract][Full Text] [Related]
19. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
20. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.
Zambello R; Crimì F; Lico A; Barilà G; Branca A; Guolo A; Varin C; Vezzaro R; Checuz L; Scapin V; Berno T; Pizzi M; Ponzoni A; De Biasi E; Vio S; Semenzato G; Zucchetta P; Lacognata C
Ann Hematol; 2019 Mar; 98(3):679-689. PubMed ID: 30539276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
